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The coronavirus disease 2019 (COVID-19) pandemic, caused 
by severe respiratory syndrome coronavirus-2 (SARS-CoV-2), is 
ongoing due to a rapid increase in the number of cases outside 
Wuhan, China.1 The high-affinity interaction of SARS-CoV-2 
with the human angiotensin-converting enzyme 2 (ACE2) re-
ceptor has been shown to mediate the entry of the virus into the 
cell.2 ACE2 is not only expressed in lung epithelial cells, but 
also in colon and terminal ileum epithelial cells.3 Accordingly, 
gastrointestinal manifestations, including diarrhea, nausea, 
and vomiting, were reported in 4% to 23.7% of COVID-19 pa-
tients.1,4 Additionally, continuous positive detection of SARS-
CoV-2 RNA in feces has been demonstrated in a previous study, 
suggesting that fecal-oral transmission is as an alternative route 
of infection.5 Furthermore, dipeptidyl peptidase 4 (DPP4), ami-
nopeptidase N (AMPN), and glutamyl aminopeptidase (AMPE) 
have been suggested to be probable SARS-CoV-2 co-receptors, 
in conjunction with ACE.6
A few studies have investigated the susceptibility of COV-
ID-19 infections in patients with chronic colitis. Therefore, we 
performed a quantitative proteomic analysis associated with 
COVID-19 utilizing tissue samples of patients with chronic 
colitis, including ulcerative colitis (UC), Crohn’s disease (CD), 
intestinal Behćet’s disease (BD), and intestinal tuberculosis 
(TB). Subsequently, the protein expression levels in these pa-
tients were compared with those of healthy controls. 
Chronic colitis patients, including those with UC (n=7), CD 
(n=7), intestinal BD (n=7), and intestinal TB (n=2), along with 
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The cellular entry of severe respiratory syndrome coronavirus-2 (SARS-CoV-2) is mediated by interaction with the human angio-
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colon mucosa samples. In conclusion, gut inflammation associated with chronic colitis does not mediate a further increase in the 
cellular entry of SARS-CoV-2.   
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healthy controls (n=7), were recruited between November 
2006 and September 2019 at the IBD Clinic at Severance Hos-
pital in Seoul, Korea. The colon mucosa tissue samples were 
obtained using colonoscopy guided biopsy of the affected 
bowel with chronic colitis. Conversely, the normal colon mu-
cosa tissue samples were obtained from healthy individuals. 
The tissue and serum samples were preserved at -80°C. This 
study was approved by the Institutional Review Board of Yon-
sei University College of Medicine (IRB No: 2012-0039-030).
For proteomic analysis, the colon mucosa tissue samples 
were lysed and labeled with tandem mass tag (TMT, Thermo 
Scientific, San Jose, CA, USA) reagents in accordance with the 
manufacturer’s instructions. The labeled peptide samples were 
pooled into a new vial and dried in a SpeedVac (Thermo Scien-
tific). Various methodologies, including strong cation exchange 
fraction, liquid chromatography (LC)-mass spectrometry (MS), 
and a database search, were performed by Poochon Scientific 
(Frederick, MD, USA). MS raw data files were searched against 
the human protein sequence databases obtained from the 
NCBI website for the database search, which was conducted 
using Proteome Discoverer 1.4 software (Thermo Scientific) 
based on the SEQUEST and percolator algorithms. 
The false positive discovery rate was set to 5%. The resulting 
Proteome Discoverer report from Poochon Scientific con-
tained the assembled proteins, along with pertinent data re-
garding the peptide sequences and spectrum match counts 
(PSM#), as well as the TMT-tag based quantification ratio. 
Unpaired Student’s t-test was used to compare the differences 
in expression between the chronic colitis patients and the 
healthy controls. A two-sided p value of < 0.05 was considered 
to be statistically significant. 
The colon mucosa tissue samples from HCs and patients 
with UC, CD, intestinal BD, and intestinal TB were collected 
and analyzed using the TMT/LC-MS/MS-based proteomic 
approach. We identified 5137 proteins from the TMT set (2 
HC vs. 2 CD vs. 2 UC vs. 2 BD vs. 2 TB) and 6154 proteins from 
a combination of two TMT sets (5 HC vs. 5 CD vs. 5 UC vs. 5 
BD). ACE2 was detected only in the first TMT set, whereas, 
DPP4, AMPN, and AMPE were detected in all TMT sets.
ACE2 expression levels were 1.18-fold higher in UC, 0.97-
fold lower in CD, 1.59-fold higher in intestinal BD, and 1.52-
fold higher in intestinal TB, compared with expression levels 
in healthy controls. However, the observed changes in expres-
sion levels were not statistically significant (Table 1, Fig. 1A). 
Furthermore, DPP4, AMPN, and AMPE expression levels did 
not differ between chronic colitis patients and healthy con-
trols (Table 1, Fig. 1B–D). 
In the present proteomics analysis, we investigated the ex-
pression levels of possible SARS-CoV-2 receptors in the intes-
tinal mucosa of chronic colitis patients. Unexpectedly, the ex-
pression levels of the SARS-CoV-2 receptor ACE2 were extremely 
low. Additionally, the quantitative analysis did not show elevat-
ed ACE expression levels in UC, CD, intestinal BD, and intesti-
nal TB patients, compared with those in healthy controls. Oth-
er than ACE2, the expression levels of several other possible 
co-receptors, including DPP4, AMPN, and AMPE, were not in-
creased in the affected UC, CD, intestinal BD, and intestinal 
TB colon mucosa samples. 
A higher expression of ACE2 has been reported in the termi-
nal ileum and colon tissues of IBD patients, compared to that in 
control patients, on the basis of immunohistochemical staining.7 
However, in agreement with our findings, no significant differ-
ences in ACE2 expression between IBD patients and healthy 
controls were observed in TMT-based shotgun proteomic stud-
ies, which utilized quantitative proteomics to conduct a high-
throughput analysis of protein expression with enhanced ac-
curacy, sensitivity, and reproducibility.8,9 Moreover, a recent 
epidemiological study conducted by An, et al.10 reported that 
SARS-CoV-2 infections were not detected in any of the 319 reg-
istered IBD patients in Wuhan, China. Hence, there is no evi-
dence to suggest an increased risk of COVID-19 in IBD patients.
Although the proteomics analysis we applied here has strong 
aspects of accuracy and repeatability, there are a few limitations 
in this study. First, the sample size was relatively small to con-
clude that gut inflammation associated with chronic colitis 
would not mediate a further increase in the cellular entry of 
SARS-CoV-2 virus. Further investigation with more samples 
would be required to prove our hypothesis. Second, although 
ACE2 serves as a receptor for viral entry, some studies have 
shown that decreased ACE2 expression could portend a higher 
risk of developing severe acute respiratory disease, including 
lung injury. Imai, et al.11 have revealed that ACE2 plays a protec-
tive role in severe lung injury in ACE2 knockout mice. More-
over, several studies have shown that although children have 
higher levels of ACE2 than adults, they have been shown to 
have fewer and less severe symptoms compared with adults.12 





UC/Con CD/Con Intestinal BD/Con Intestinal TB/Con Unique peptides/
∑# PSMsFC p value FC p value FC p value FC p value
Q9BYF1 ACE2 1.18 0.739 0.97 0.142 1.59 0.325 1.52 0.397 1/1
P27487 DPP4 0.91 0.453 0.91 0.475 1.45 0.261 1.23 0.191 9/12
P15144 AMPN 0.88 0.531 0.98 0.910 1.76 0.256 1.41 0.178 26/67
Q07075 AMPE 1.02 0.969 1.15 0.769 3.56 0.282 2.00 0.223 6/7
UC, ulcerative colitis; CD, Crohn’s colitis; BD, Behćet’s disease; TB, tuberculosis; FC, fold change; ∑# PSMs, total numbers of identified peptide sequences; ACE2, 
angio-tensin-converting enzyme 2; DPP4, dipeptidyl peptidase 4; AMPN, aminopepti-dase N; AMPE, glutamyl aminopeptidase.
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In order to elucidate the functional role of ACE2 in specific dis-
eases (e.g., chronic colitis), it is necessary to specifically exam-
ine it using specific disease models, such as human IBD mim-
icking animal colitis models.
Nevertheless, our data support the finding that gut inflam-
mation associated with chronic colitis does not further poten-
tiate the cellular entry of SARS-CoV-2. 
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Fig. 1. Expression of SARS-CoV-2 receptor proteins in healthy controls (HC, open circle) and patients with Crohn’s disease (CD, open triangle), ulcer-
ative colitis (UC, open quadrangle), intestinal Behćet’s disease (BD, open inverted triangle), and intestinal tuberculosis (TB, open diamond). (A) ACE2, 
(B) DPP4, (C) AMPN, and (D) AMPE. Data are representative of means±standard errors. ACE2, angio-tensin-converting enzyme 2; DPP4, dipeptidyl 
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